[Chemotherapy of prostatic carcinoma]

Area of Science:

• Oncology
• Urology
• Medical Research

Context:

• Hormone-refractory prostate cancer presents significant treatment challenges.
• Current chemotherapy regimens offer limited efficacy in advanced stages.

Purpose:

• To evaluate the effectiveness of chemotherapy in hormone-refractory prostate carcinoma.
• To compare primary chemotherapy with standard hormone therapy for survival outcomes.
• To assess the benefits of combination chemotherapy versus single-agent therapy.

Summary:

• Chemotherapy for hormone-refractory prostate carcinomas yields disappointing results, with only partial remissions observed.
• Prospective studies show no survival advantage for primary chemotherapy over standard hormone therapy in metastatic prostate cancer.
• The superiority of combination chemotherapy over single-agent therapy for prostate cancer remains unproven.

Impact:

• Current chemotherapy approaches for prostate cancer are insufficient for achieving complete remission.
• Evidence suggests chemotherapy for prostate cancer should be reserved for controlled clinical trials.
• Future research should focus on testing novel agents and combination therapies within rigorous study designs.